110 I. Nazarenko et al. recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Devel- opment. 1999;126:3047–55. 65. Smits A, Hermansson M, Nistér M, Karnushina I, Heldin CH, Westermark B, et al. Rat brain capillary endo- thelial cells express functional PDGF B-type receptors. Growth Factors. 1989;2:1–8. 66. Fruttiger M, Calver AR, Richardson WD. Platelet-derived growth factor is constitutively secreted from neuronal cell bodies but not from axons. Curr Biol. 2000;10:1283–6. 67. Noble M, Murray K, Stroobant P, Waterﬁeld MD, Riddle P. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/ type-2 astrocyte progenitor cell. Nature. 1988;333:560–2. 68. Yeh H-J, Ruit KG, Wang Y-X, Parks WC, Snider WD, Deuel TF. PDGF A-chain gene is expressed by mammalian neurons during development and in maturity. Cell. 1991;64: 209–16. 69. Raff MC, Lillien L, Richardson WD, Burne JF, Noble M. Platelet-derived growth factor from astrocytes drives the lock that times oligodendrocyte development in culture. Nature. 1988;333:562–5. 70. Richardson WD, Pringle N, Mosley MJ, Westermark B, Dubois-Dalcq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell. 1988;53:309–19. 71. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, et al. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron. 1998;20:869–82. 72. Fruttiger M, Karlsson L, Hall AC, Abramsson A, Calver AR, Bostrom H, et al. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice. Devel- opment. 1999;126:457–67. 73. van Heyningen P, Calver AR, Richardson WD. Control of progenitor cell number by mitogen supply and demand. Curr Biol. 2001;11:232–41. 74. Woodruff RH, Fruttiger M, Richardson WD, Franklin JM. Platelet-derived growth factor regulates oligodendrocyte pro- genitor number in adult CNS and their response following CNS demyelination. Mol Cell Neurosci. 2004;25:252–62. 75. Hu JG, Fu SL, Wang YX, Li Y, Jiang XY, Wang XF, et al. Platelet-derived growth factor-AA mediates oligodendrocyte lineage differentiation through activation of extracellular signal-regulated kinase signaling pathway. Neuroscience. 2008;151:138–47. 76. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alpha-- positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. 2006;51:187–99. 77. Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A. Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci. 2006; 26:7907–18. 78. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classiﬁcation of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. 79. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445–53. 80. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51:2164–72. 81. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984; 44:753–60. 82. Cancer Genome Atlas Research Network. Comprehensive genomic characterization deﬁnes human glioblastoma genes and core pathways. Nature. 2008;455:1061–8. 83. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992;89:2965–9. 84. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor tran- scripts from ampliﬁed rearranged genes in human glioblasto- mas. Proc Natl Acad Sci USA. 1990;87:8602–6. 85. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16:748–54. 86. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligoden- drogliomas. Neurosurgery. 1998;42:341–6. 87. Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer. 2009;101:973–82. 88. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T. Overexpression and ampliﬁcation of alpha- PDGF receptor gene lacking exons coding for a portion of the extracellular region in a malignant glioma. Tohoku J Exp Med. 1992;168:265–9. 89. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA. 2005;102:14344–9. 90. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Cancer Genome Atlas Research Net- work. Integrated genomic analysis identiﬁes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17: 98–110. 91. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-ampliﬁed glioblastomas. Genes Dev. 2010;24:2205–18. 92. Sørensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neuroﬁbromatosis. Survival and malig- nant neoplasms. N Engl J Med. 1986;314:1010–15. 93. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3’- kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003;13:507–18. 94. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14:391–6. 95. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004;3:430–46. 96. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6: 217–23; discussion 23–4. 97. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12.